LL-37 vs VIP
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Also: Vasoactive Intestinal Peptide, Aviptadil
A naturally occurring peptide with immunomodulatory and anti-inflammatory effects. Being studied for ARDS, pulmonary hypertension, and autoimmune conditions.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
Detailed Comparison
| Attribute | LL-37 | VIP |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. | VIP binds to VPAC1 and VPAC2 receptors, triggering anti-inflammatory cascades. It relaxes smooth muscle, vasodilates, inhibits pro-inflammatory cytokines, and promotes regulatory T-cell function. Has broad immunomodulatory effects. |
| Common Dosing | 100-200 mcg daily Once daily | 50-100 mcg intranasal daily 1-2x daily, intranasal |
| Administration | Subcutaneous injection or topical | IV infusion, inhaled, or intranasal |
| Typical Duration | Variable by protocol | Variable by indication |
| Best Time to Take | Morning | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. | Clinical trials for COVID-19 ARDS showed promising results. Research demonstrates benefits in pulmonary arterial hypertension. Studies show potential for autoimmune conditions like rheumatoid arthritis and inflammatory bowel disease. |
Frequently Asked Questions: LL-37 vs VIP
What is the difference between LL-37 and VIP?
LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. VIP is a immune peptide that a naturally occurring peptide with immunomodulatory and anti-inflammatory effects. being studied for ards, pulmonary hypertension, and autoimmune conditions. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or VIP?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while VIP is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and VIP be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and VIP together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.